Abstract:
Objective To evaluate response rates and survival durations after hepatic arterial chemoembolization (HACE) in patients with liver metastasis from pancreatic carcinoma, and to analyze factors affecting patient survival.
Methods The medical records of patients with liver metastasis from pancreatic carcinoma who underwent HACE at the general hospital of Chinese People's Liberation Army from 2002 to 2011 were reviewed. The radiologic tumor response rates, overall survival (OS), and progression-free survival durations were calculated. Patient, tumor, and treatment variables were analyzed to identify factors influencing survival.
Results One hundred and twenty-five patients underwent 265 HACE sessions. Of the 105 patients in whom radiologic responses could be evaluated, 12 (11%) had partial responses, 17 (16%) had minor responses, 68 (65%) had stable diseases, and 8 (8%) had progressive diseases. The median OS and progression-free survival durations were 6.7 months and 3.8 months, respectively. Multivariate analysis showed that >75% liver involvement and high lactate dehydrogenase levels were associated with short OS. Patients who had radiologic responses to HACE had a longer median OS duration than patients who did not (15.8 months vs. 6.1 months; P = 0.0005). Patients with > 75% liver involvement had a median OS duration of only 2.4 months.
Conclusion HACE resulted in radiologic response or disease stabilization in most patients with liver metastasis from pancreatic carcinoma. The extent of liver involvement, baseline lactate dehydrogenase levels, and response to therapy were found to be significant predictors of OS after HACE.
下载: